Drug-Induced Liver Injury Associated with HIV Medications

Clinics in Liver Disease

Volumn 11, Issue 3, 2007, Pages 615-639

  Jain, Mamta K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; COTRIMOXAZOLE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FLUCONAZOLE; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PEGINTERFERON; RIBAVIRIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ABDOMINAL PAIN; ANAPHYLAXIS; CD4 LYMPHOCYTE COUNT; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FATTY LIVER; GENETIC POLYMORPHISM; GENETIC SCREENING; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERBILIRUBINEMIA; INFECTION RISK; KIDNEY FAILURE; LACTIC ACIDOSIS; LETHARGY; LIVER BIOPSY; LIVER FAILURE; LIVER INJURY; LIVER MITOCHONDRION; MITOCHONDRIAL TOXICITY; NAUSEA; NAUSEA AND VOMITING; OPPORTUNISTIC INFECTION; PARESTHESIA; PHARMACOGENETICS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; THERAPY EFFECT; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ANTI-HIV AGENTS; HUMANS; LIVER; LIVER DISEASES; PHARMACOGENETICS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 34548122764     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.06.008     Document Type: Review

References (109)

1. Hogg R.S., O'Shaughnessy M.V., Gataric N., et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 349 9061 (1997) 1294
2. Palella Jr. F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 13 (1998) 853-860
3. Lohse N., Hansen A.B., Pedersen G., et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146 2 (2007) 87-95
4. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2 8 (2003) 624-634
5. Hammer S.M., Squires K.E., Hughes M.D., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337 11 (1997) 725-733
6. Katzenstein D.A., Hammer S.M., Hughes M.D., et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 335 15 (1996) 1091-1098
7. Palmon R., Koo B.C., Shoultz D.A., et al. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 29 4 (2002) 340-345
8. Hernandez L.V., Gilson I., Jacobson J., et al. Antiretroviral hepatotoxicity in human immunodeficiency virus-infected patients. Aliment Pharmacol Ther 15 10 (2001) 1627-1632
9. Aceti A., Pasquazzi C., Zechini B., et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 29 1 (2002) 41-48
10. den Brinker M., Wit F.W., Wertheim-van Dillen P.M., et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14 18 (2000) 2895-2902
11. Gisolf E.H., Dreezen C., Danner S.A., et al. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 31 5 (2000) 1234-1239
12. Nunez M., Lana R., Mendoza J.L., et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 27 5 (2001) 426-431
13. Nunez M., Rios P., Martin-Carbonero L., et al. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 30 1 (2002) 65-68
14. Puoti M., Torti C., Ripamonti D., et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 32 3 (2003) 259-267
15. Sanne I., Mommeja-Marin H., Hinkle J., et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 191 6 (2005) 825-829
16. Servin-Abad L., Molina E., Baracco G., et al. Liver enzymes elevation after HAART in HIV-HCV co-infection. J Viral Hepat 12 4 (2005) 429-434
17. Servoss J.C., Kitch D.W., Andersen J.W., et al. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr 43 3 (2006) 320-323
18. Sherman K.E., Shire N.J., Cernohous P., et al. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. Clin Infect Dis 41 8 (2005) 1186-1195
19. Sulkowski M.S., Mehta S.H., Chaisson R.E., et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 18 17 (2004) 2277-2284
20. Sulkowski M.S., Thomas D.L., Chaisson R.E., et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283 1 (2000) 74-80
21. Wit F.W., Weverling G.J., Weel J., et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 186 1 (2002) 23-31
22. Sulkowski M.S., Thomas D.L., Mehta S.H., et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35 1 (2002) 182-189
23. Bonnet F., Lawson-Ayayi S., Thiebaut R., et al. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. Clin Infect Dis 35 10 (2002) 1231-1237
24. Clark S.J., Creighton S., Portmann B., et al. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. J Hepatol 36 2 (2002) 295-301
25. Ena J., Amador C., Benito C., et al. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS 14 11 (2003) 776-781
26. Bonfanti P., Ricci E., Penco G., et al. Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir. AIDS 19 13 (2005) 1433-1434
27. De Maat M.M., Mathot R.A., Veldkamp A.I., et al. Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals. Pharmacol Res 46 3 (2002) 295-300
28. Saves M., Raffi F., Clevenbergh P., et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 44 12 (2000) 3451-3455
29. Sulkowski M.S. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 38 Suppl 2 (2004) S90-S97
30. Torti C., Lapadula G., Puoti M., et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. J Acquir Immune Defic Syndr 41 2 (2006) 180-185
31. French A.L., Benning L., Anastos K., et al. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin Infect Dis 39 3 (2004) 402-410
32. Maida I., Nunez M., Rios M.J., et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 42 2 (2006) 177-182
33. Martinez E., Blanco J.L., Arnaiz J.A., et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15 10 (2001) 1261-1268
34. Kramer J.R., Giordano T.P., Souchek J., et al. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 42 3 (2005) 309-314
35. Qurishi N., Kreuzberg C., Luchters G., et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362 9397 (2003) 1708-1713
36. Rancinan C., Neau D., Saves M., et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy?. AIDS 16 10 (2002) 1357-1362
37. Mocroft A., Soriano V., Rockstroh J., et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. AIDS 19 18 (2005) 2117-2125
38. Monforte Ade A., Bugarini R., Pezzotti P., et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 28 2 (2001) 114-123
39. Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 3 (2001) 492-497
40. Mocroft A., Phillips A.N., Soriano V., et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 21 9 (2005) 743-752
41. Saves M., Vandentorren S., Daucourt V., et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 13 17 (1999) F115-F121
42. Livry C., Binquet C., Sgro C., et al. Acute liver enzyme elevations in HIV-1-infected patients. HIV Clin Trials 4 6 (2003) 400-410
43. Bessesen M., Ives D., Condreay L., et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 28 5 (1999) 1032-1035
44. Jain M.K., Parekh N.K., Hester J., et al. Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS 20 12 (2006) 817-822
45. Chung R.T., Evans S.R., Yang Y., et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 16 14 (2002) 1915-1923
46. Gavazzi G., Bouchard O., Leclercq P., et al. Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders?. AIDS Res Hum Retroviruses 16 11 (2000) 1021-1023
47. John M., Flexman J., and French M.A. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?. AIDS 12 17 (1998) 2289-2293
48. Rutschmann O.T., Negro F., Hirschel B., et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 177 3 (1998) 783-785
49. Vento S., Garofano T., Renzini C., et al. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 12 1 (1998) 116-117
50. Martin-Carbonero L., Nunez M., Rios P., et al. Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 16 10 (2002) 1423-1425
51. Stone S.F., Lee S., Keane N.M., et al. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J Infect Dis 186 10 (2002) 1498-1502
52. Uberti-Foppa C., De Bona A., Morsica G., et al. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 33 2 (2003) 146-152
53. Maida I., Babudieri S., Selva C., et al. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes. AIDS Res Hum Retroviruses 22 2 (2006) 139-143
54. Aranzabal L., Casado J.L., Moya J., et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 40 4 (2005) 588-593
55. Murcia J.M., Boix V., Merino E., et al. Drug toxicity or syndrome of immune restoration causing fulminant cirrhosis after HAART-induced immune recovery. Eur J Clin Microbiol Infect Dis 21 2 (2002) 153-155
56. Macias J., Castellano V., Merchante N., et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 18 5 (2004) 767-774
57. Mehta S.H., Thomas D.L., Torbenson M., et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 41 1 (2005) 123-131
58. Brau N., Salvatore M., Rios-Bedoya C.F., et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 44 1 (2006) 47-55
59. Meraviglia P., Schiavini M., Castagna A., et al. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Med 5 5 (2004) 334-343
60. Martin-Carbonero L., Nunez M., Gonzalez-Lahoz J., et al. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 4 2 (2003) 115-120
61. Verucchi G., Calza L., Manfredi R., et al. Incidence of liver toxicity in HIV-infected patients receiving isolated dual nucleoside analogue antiretroviral therapy. J Acquir Immune Defic Syndr 33 4 (2003) 546-548
62. Bleeker-Rovers C.P., Kadir S.W., van Leusen R., et al. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Neth J Med 57 5 (2000) 190-193
63. Charton-Bain M.C., Flamant M., Aubertin J.M., et al. [Lactic acidosis and hepatic mitochondrial changes during a treatment with zidovudine]. Gastroenterol Clin Biol 21 12 (1997) 979-981 [in French]
64. Finkle H.I. Hepatic mitochondrial toxicity from nucleoside analog therapy. Arch Pathol Lab Med 123 3 (1999) 189
65. John M., Moore C.B., James I.R., et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 15 6 (2001) 717-723
66. Olano J.P., Borucki M.J., Wen J.W., et al. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis 21 4 (1995) 973-976
67. Coghlan M.E., Sommadossi J.P., Jhala N.C., et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 33 11 (2001) 1914-1921
68. Gerard Y., Maulin L., Yazdanpanah Y., et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 14 17 (2000) 2723-2730
69. Miller K.D., Cameron M., Wood L.V., et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 133 3 (2000) 192-196
70. Mokrzycki M.H., Harris C., May H., et al. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 30 1 (2000) 198-200
71. Ogedegbe A.E., Thomas D.L., and Diehl A.M. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 3 6 (2003) 329-337
72. Carr A., Morey A., Mallon P., et al. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 357 9266 (2001) 1412-1414
73. Mallal S., Nolan D., Witt C., et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359 9308 (2002) 727-732
74. Montaner J.S., Cote H.C., Harris M., et al. Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. Clin Infect Dis 38 Suppl 2 (2004) S73-S79
75. Moyle G.J., Datta D., Mandalia S., et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 16 10 (2002) 1341-1349
76. Gerard Y., Viget N., Yazdanpanah Y., et al. Hyperlactataemia during antiretroviral therapy: incidences, clinical data and treatment. Therapie 58 2 (2003) 153-158
77. Lonergan J.T., Behling C., Pfander H., et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 31 1 (2000) 162-166
78. Hetherington S., Hughes A.R., Mosteller M., et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359 9312 (2002) 1121-1122
79. Stekler J., Maenza J., Stevens C., et al. Abacavir hypersensitivity reaction in primary HIV infection. AIDS 20 9 (2006) 1269-1274
80. Hughes D.A., Vilar F.J., Ward C.C., et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14 6 (2004) 335-342
81. Arnaudo E., Dalakas M., Shanske S., et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337 8740 (1991) 508-510
82. Cote H.C., Brumme Z.L., Craib K.J., et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346 11 (2002) 811-820
83. Bissell D.M., Gores G.J., Laskin D.L., et al. Drug-induced liver injury: mechanisms and test systems. Hepatology 33 4 (2001) 1009-1013
84. Mira J.A., Macias J., Giron-Gonzalez J.A., et al. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 58 1 (2006) 140-146
85. Lyons F., Hopkins S., Kelleher B., et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 7 4 (2006) 255-260
86. Dieterich D.T., Robinson P.A., Love J., et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 38 Suppl 2 (2004) S80-S89
87. Clarke S., Harrington P., Condon C., et al. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Int J STD AIDS 11 5 (2000) 336-337
88. Centers for Disease Control and Prevention (CDC). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 49 51-52 (2001) 1153-1156
89. Benn P.D., Mercey D.E., Brink N., et al. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet 357 9257 (2001) 687-688
90. Gonzalez de Requena D., Nunez M., Jimenez-Nacher I., et al. Liver toxicity caused by nevirapine. AIDS 16 2 (2002) 290-291
91. Dailly E., Billaud E., Reliquet V., et al. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol 60 5 (2004) 343-348
92. Gonzalez-Requena D., Nunez M., Jimenez-Nacher I., et al. Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection. AIDS Res Hum Retroviruses 20 7 (2004) 698-700
93. Kappelhoff B.S., van Leth F., Robinson P.A., et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations?. Antivir Ther 10 4 (2005) 489-498
94. Martin A.M., Nolan D., James I., et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19 1 (2005) 97-99
95. Haas D.W., Smeaton L.M., Shafer R.W., et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis 192 11 (2005) 1931-1942
96. Rotger M., Colombo S., Furrer H., et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 15 1 (2005) 1-5
97. Ritchie M.D., Haas D.W., Motsinger A.A., et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 43 6 (2006) 779-782
98. Haas D.W., Bartlett J.A., Andersen J.W., et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 43 6 (2006) 783-786
99. Cooper C.L., Parbhakar M.A., and Angel J.B. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 34 9 (2002) 1259-1263
100. Zucker S.D., Qin X., Rouster S.D., et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 98 22 (2001) 12671-12676
101. Rodriguez-Novoa S., Martin-Carbonero L., Barreiro P., et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21 1 (2007) 41-46
102. Rodriguez-Rosado R., Garcia-Samaniego J., and Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 12 10 (1998) 1256
103. Tipranavir (Aptivus) [package insert] (2007), Boehringer Ingelheim Pharmaceuticals, Ridgefield (CT)
104. Darunavir (Prezista) [package insert] (2006), Tibotec, Inc, Gurabo (Puerto Rico)
105. Abrescia N., D'Abbraccio M., Figoni M., et al. Hepatotoxicity of antiretroviral drugs. Curr Pharm Des 11 28 (2005) 3697-3710
106. Hsu A., Granneman G.R., and Bertz R.J. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35 4 (1998) 275-291
107. Canta F., Marrone R., Bonora S., et al. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J Antimicrob Chemother 55 2 (2005) 280-281
108. Molto J., Valle M., Blanco A., et al. Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis. Clin Pharmacokinet 46 1 (2007) 85-92
109. Sulkowski M.S., and Thomas D.L. Hepatitis C in the HIV-infected person. Ann Intern Med 138 3 (2003) 197-207